The limited duration of humoral responses to vaccination is a key issue in the fight against infectious diseases, as antibody levels wane over time, leaving individuals vulnerable to reinfection.
Researchers at Stanford have found that a vaccine, enhanced with adjuvants that imprint an antiviral state on innate immune cells and non-hematopoietic organ cells, could confer lasting nonspecific protection against diverse pathogens.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Stanford researchers have developed a multi-omics method for predicting the strength and durability of immune responses to vaccines shortly after vaccination. The COVID-19 pandemic was a grave demonstration of the threat pandemics pose to global public health.